

# International Consensus on Diverticulosis and Diverticular Disease. Statements from the 3rd International Symposium on Diverticular Disease

---

**Tursi, Antonio; Brandimarte, Giovanni; Di Mario, Francesco; Lanas, Angel; Scarpignato, Carmelo; Bafutto, Mauro; Barbara, Giovanni; Bassotti, Gabrio; Binda, Gian Andrea; Biondi, Alberto; ...**

*Source / Izvornik:* **Journal of Gastrointestinal and Liver Diseases, 2020, 28, 57 - 66**

**Journal article, Published version**

**Rad u časopisu, Objavljena verzija rada (izdavačev PDF)**

<https://doi.org/10.15403/jgld-562>

*Permanent link / Trajna poveznica:* <https://um.nsk.hr/um:nbn:hr:184:580062>

*Rights / Prava:* [In copyright](#)/[Zaštićeno autorskim pravom.](#)

*Download date / Datum preuzimanja:* **2024-08-25**



*Repository / Repozitorij:*

[Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository](#)



## International Consensus on Diverticulosis and Diverticular Disease. Statements from the 3rd International Symposium on Diverticular Disease

Antonio Tursi<sup>1</sup>, Giovanni Brandimarte<sup>2</sup>, Francesco Di Mario<sup>3</sup>, Angel Lanas<sup>4</sup>, Carmelo Scarpignato<sup>5</sup>, Mauro Bafutto<sup>6</sup>, Giovanni Barbara<sup>7</sup>, Gabrio Bassotti<sup>8</sup>, Gian Andrea Binda<sup>9</sup>, Alberto Biondi<sup>10</sup>, Sebastiano Biondo<sup>11</sup>, Ginevra Cambie<sup>3</sup>, Claudio Cassieri<sup>2</sup>, Antonio Crucitti<sup>12</sup>, Dan L. Dumitrascu<sup>13</sup>, Walter Elisei<sup>14</sup>, Ricardo Escalante<sup>15</sup>, László Herszenyi<sup>6</sup>, Wolfgang Kruis<sup>17</sup>, Juozas Kupcinskas<sup>18</sup>, Adi Lahat<sup>19</sup>, Piera G. Lecca<sup>2</sup>, Giovanni Maconi<sup>20</sup>, Peter Malfertheiner<sup>21</sup>, Andrea Mazzari<sup>12</sup>, Fermin Mearin<sup>22</sup>, Tomica Milosavljevic<sup>23</sup>, Gerardo Nardone<sup>24</sup>, Enio Chavez de Oliveira<sup>25</sup>, Alfredo Papa<sup>26</sup>, Savvas Papagrigroriadis<sup>27</sup>, Miguel Pera<sup>28</sup>, Roberto Persiani<sup>10</sup>, Marcello Picchio<sup>29</sup>, Jaroslaw Regula<sup>30</sup>, Davor Štimac<sup>31</sup>, Neil Stollman<sup>32</sup>, Lisa L. Strate<sup>33</sup>, Alessandra Violi<sup>3</sup>, Marjorie M.D. Walker<sup>34</sup>

1) Gastroenterology Service, ASL BAT, Andria (BT), Italy; 2) Division of Internal Medicine and Gastroenterology, "Cristo Re" Hospital, Rome, Italy; 3) Department of Medicine and Surgery, Gastroenterology Unit, University of Parma, Parma, Italy; 4) Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, University of Zaragoza, IIS Aragón, Zaragoza, Spain; 5) Faculty of Medical Sciences, United Campus of Malta, San Ġiljan, Malta; 6) Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda, Rua 246, 25 Setor Coimbra, Goiânia, Goiás, Brazil; 7) Department of Clinical Medicine, Section of Gastroenterology, "S. Orsola" Hospital, University of Bologna, Bologna, Italy; 8) Department of Clinical and Experimental Medicine, Gastroenterology and Hepatology Section, "Santa Maria della Misericordia" Hospital, University of Perugia, San Sisto (PG), Italy; 9) Department of Surgery, "Galliera" Hospital, Genoa, Italy; 10) Department of Surgical Sciences, First General Surgery Unit, Catholic University, "A. Gemelli" University Hospital, Rome, Italy; 11) Department of General and Digestive Surgery, Colorectal Unit, Bellvitge University Hospital and IDIBELL, University of Barcelona, Barcelona, Spain; 12) Division of General Surgery, "Cristo Re" Hospital, Rome, Italy; 13) 2nd Medical Department, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Romania; 14) Division of Gastroenterology, ASL Roma 6, Albano Laziale (Roma), Italy; 15) Universidad Central de Venezuela, Loira Medical Center, Caracas, Venezuela; 16) 2nd Department of Medicine, Semmelweis University, H-1088 Budapest, Hungary; 17) Innere Medizin, Evangelische Krankenhaus Kalk, Cologne, Germany; 18) Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas; Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania; 19) Department of Gastroenterology, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan 52651, Israel; 20) Gastrointestinal Unit, Department of Clinical Sciences, "L.Sacco" University Hospital, Milan, Italy; 21) Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, Magdeburg, Germany; 22) Servicio Aparato Digestivo, Centro Médico Teknon, Barcelona, Spain; 23) Clinical Centre of Serbia, University of Belgrade, Serbia; 24) Department of Clinical and Experimental Medicine, University "Federico II", Naples, Italy; 25) Hospital Ortopédico de Goiania (St Aeroporto), Goiânia, Goiás, Brazil; 26) Division of Internal Medicine and Gastroenterology, CIC "Columbus", Catholic University, "A. Gemelli" University Hospital, Rome, Italy; 27) Department of Colorectal Surgery, King's College Hospital, London, United Kingdom; 28) Sección de Cirugía Gastrointestinal, Hospital Universitari del Mar, Barcelona, Spain; 29) Division of General Surgery, "P. Colombo" Hospital, ASL Roma 6, Velletri (Roma), Italy; 30) Department of Gastroenterology, Hepatology and Clinical Oncology, Medical Postgraduate Education Centre; Department of Gastrointestinal Oncology, Maria Skłodowska-Curie Clinical Oncology Institute, Warsaw, Poland; 31) Division of Internal Medicine, University Hospital, Rijeka, Croatia; 32) Division of Gastroenterology, Department of Medicine, University of California San Francisco, Oakland, CA, USA; 33) Division of Gastroenterology, Department of Medicine, Harborview Medical Center, University of Washington Medical School, Seattle, Washington, USA; 34) University of Newcastle, Faculty of Health and Medicine, School of Medicine & Public Health, Australian Gastrointestinal Research Alliance, Callaghan NSW 2308, Australia

### ABSTRACT

The statements produced by the Chairmen and Speakers of the 3rd International Symposium on Diverticular Disease, held in Madrid on April 11th-13th 2019, are reported. Topics such as current and evolving concepts on the pathogenesis, the course of the disease, the news in diagnosing, hot topics in medical and surgical treatments, and finally, critical issues on the disease were reviewed by the Chairmen who proposed 39 statements graded according to level of evidence and strength of recommendation. Each topic was explored focusing on the more relevant clinical questions. The vote was conducted on a 6-point scale and consensus was defined a priori as 67% agreement of the participants. The voting group consisted of 124 physicians from 18 countries, and agreement with all statements was provided. Comments were added explaining some controversial areas.

---

*Address for correspondence:*

**Antonio Tursi, MD**

Via Torino, 49

76123 Andria (BT) – Italy

[antotursi@tiscali.it](mailto:antotursi@tiscali.it)

**Key words:** diverticulosis – diverticular disease – diverticulitis – consensus – diagnosis – medical therapy – surgical therapy.

**Abbreviations:** AD: acute diverticulitis; 5-ASA: 5-aminosalicylic-acid; CRP: C-reactive protein; CE-CT: contrast-enhanced computer tomography; CRC: colorectal cancer; CT: computer tomography; DD: diverticular disease; DICA: Diverticula Inflammation and Complications Assessment; EL: evidence level; FC: fecal calprotectin; IBS: irritable bowel syndrome; IUS: intestinal ultrasound; RG: recommendation grade; SCAD: segmental colitis associated with diverticulosis; SUDD: symptomatic uncomplicated diverticular disease ; TNF $\alpha$ : tumour necrosis factor alpha.

## INTRODUCTION

Diverticulosis of the colon is the most frequent anatomical alteration of the colon in the developed countries, and the highest rates occur in the United States and Europe. This condition nowadays ranks as fifth most important gastrointestinal disease in terms of direct and indirect costs [1, 2]. When diverticulosis becomes symptomatic, it is called “diverticular disease” (DD), a term generally including symptomatic uncomplicated diverticular disease (SUDD) and acute diverticulitis (AD) [1, 2]

Although the pathogenesis and management of diverticulosis and DD remain uncertain, new hypotheses and observations are changing the pharmacological and surgical management of DD.

Recommendations for the diagnosis and treatment of DD have been issued by many medical societies in various countries. However, these recommendations are often conflicting [3, 4], generating uncertainties in the clinician and dissatisfaction in patients.

We have summarised the current perspective on DD in this consensus conference report, aiming to develop guidelines for the clinical, diagnostic and therapeutic management of DD in light of the presentations during the 3rd International Symposium on Diverticular Disease, held in Madrid on April 11<sup>th</sup>-13<sup>th</sup>, 2019.

## METHODS

The primary aim of this document was to provide clinical guidelines for appropriate definition, diagnosis and management of diverticulosis and DD according to the opinion of the participants to the 3rd International Symposium on Diverticular Disease, held in Madrid on April 11-13, 2019. The promoters of this initiative were the Chairmen of this International Symposium (A.T., F.D.M., G.B., A.L., C.S.). This International Symposium on Diverticular Disease was constituted by six main sessions (current and evolving concepts on the pathogenesis, news on the course of the disease, the news in diagnosing, hot topics in medical therapy, hot topics in surgical treatments, and finally critical issues on the disease). The evidence-based Delphi-like process developed consensus statements following proposals by designated speakers. The process allowed individual feedback and changes of views during the process regulated by the coordinators of each session and the Chairmen of the Symposium.

The principal steps in the process were: (a) selection of the consensus group; (b) identification of areas of clinical

importance; (c) systematic literature reviews by using Medline/ PubMed and the Cochrane Database to identify evidence to support each statement, draft statements and discussion with the coordinators of each session and the Chairmen of the Symposium supported by the evidence specific to each statement. The modified statements of the 2nd International Symposium [5] were used to define statements of this Symposium. Evidence-based discussions with key references were provided for each statement, and a two-rounds assessing statements was conducted.

Each recommendation was graded according to the Oxford Centre for Evidence-Based Medicine, according to the level of evidence (EL) and grade of recommendation (RG) [6]. Participants, constituted by multi-disciplinary professionals/experts such as gastroenterologists, gastrointestinal endoscopists, surgeons, pathologists, internists, infectious diseases and general practitioners, were asked to vote each statement linked to the session at the ending of the same session. Chairmen, speakers, and members of the scientific board did not take part to vote statements. The agreement/disagreement level was scored on a six-point Likert scale as follows: A+: strongly agree; A:

agree with minor reservations; A-: agree with major reservations; D-: disagree with major reservations;

D: disagree with minor reservations; D+: strongly disagree. Level of agreement was expressed as percentage of each point of the scale. Consensus was defined a priori as agreement by at least 67% of respondents.

The format of the following recommendations comprises the question, the statement, its level of evidence and strength of recommendation, and the percentage agreement of the global consensus group on the final version.

In the present document the statements are accompanied by comments made by Chairmen of the Meeting. In some areas the evidence level is low, reflecting the lack of randomised trials and/or good quality studies. For some topics only the expert opinion was considered, where appropriate.

Analysis was performed only assessing participant voting all statements.

## STATEMENTS

One hundred and twenty-four participants voted all statements. They came from 18 countries: 1 from Australia, 5 from Bulgaria, 1 from Croatia, 1 from Germany, 1 from Israel, 60 from Italy, 3 from Mexico, 1 from The Netherlands, 2 from Poland, 2 from Portugal, 2 from Romania, 3 from Russia, 1 from Serbia, 2 from Slovakia, 1 from Slovenia, 3 from Spain, 3 from Tunisia, 1

from Hungary, and 2 from United States of America. One hundred and two were gastroenterologists, 15 surgeons, 3 internists, 3 general practitioners, and 1 specialist on infectious diseases.

## 1. Pathogenesis

**1.1 There is no sufficient evidence that fiber intake prevents the development of diverticulosis. [EL: 2b; GR: B]**

Consensus levels of agreement: A+ 38.71%; A 41.94%; A- 11.29%; D- 3.23%; D 2.42%; D+ 2.42%.

**1.2 Diverticular disease and diverticulitis are more likely to develop in individuals with genetic predisposition. [EL: 1b; GR: A]**

Consensus levels of agreement: A+ 41.13%; A 37.10%; A- 16.94%; D- 1.61%; D 3.23%; D+ 0%.

**1.3 The routine clinical use of genetic markers is not recommended for the prevention, diagnosis and management of diverticular diseases. [EL: 1b; GR: A]**

Consensus levels of agreement: A+ 70.16%; A 13.71%; A- 14.52%; D- 0%; D 0.81%; D+ 0.81%.

**1.4 Neuromuscular dysfunction represents a relevant pathogenetic factor in colonic diverticulosis. [EL: 3a; GR: C]**

Consensus levels of agreement: A+ 49.19%; A 38.71%; A- 10.48%; D- 1.61%; D 0%; D+ 0%.

**1.5 Colonic motor and sensory abnormalities may play a role in the genesis of abdominal pain in patients with colonoscopy symptomatic uncomplicated diverticular disease (SUDD). [EL: 4a; GR: C]**

Consensus levels of agreement: A+ 39.52%; A 46.77%; A- 11.29%; D- 1.61%; D 0%; D+ 0.81%.

**1.6 In community subjects and patients attending colonoscopy with no prior history of diverticulitis and with asymptomatic diverticulosis and no endoscopic inflammation it is highly unlikely there will be inflammatory changes in biopsy of the intervening colonic mucosa. [EL: 1b; GR: A]**

Consensus levels of agreement: A+ 56.45%; A 21.77%; A- 12.90%; D- 4.03%; D 4.03%; D+ 0.81%.

**1.7 Patients with symptomatic uncomplicated diverticular disease (SUDD) may have low-grade inflammatory changes at the molecular level and microbiome in the biopsy without endoscopic inflammation. [EL 3a; GR: B]**

Consensus levels of agreement: A+ 39.52%; A 45.16%; A- 14.52%; D- 0.81%; D 0%; D+ 0%.

**1.8 A diet high in dietary fiber is associated with a decreased risk of diverticulitis. [EL: 2b; GR: D]**

Consensus levels of agreement: A+ 52.42%; A 40.32%; A- 2.42%; D- 3.23%; D 0%; D+ 1.61%.

**1.9 Obesity is associated with an increased risk of diverticulitis and diverticular bleeding. [EL: 2a; GR: D]**

Consensus levels of agreement: A+ 67.74%; A 24.19%; A- 3.23%; D- 2.42%; D 1.61%; D+ 0.81%.

## Comments

These statements point out the new evidences on the pathogenesis of diverticulosis and diverticular disease. The first three statements point out the role of genetic factors to the development of DD and AD [7-14]. The fourth and fifth statements point out the significant role of neuromuscular abnormalities in the pathogenesis of diverticulosis and DD [15-20]. The sixth and the seventh statement point out that diverticulosis is a merely expression of an anatomical alteration [21-23], while symptomatic uncomplicated diverticular disease (SUDD) may have overt inflammation microscopic inflammation even without any endoscopic inflammation [24, 25]. The last two statements point out the role of high fiber diet in reducing the risk of acute diverticulitis [26-30], and more recent evidences are available about the role of obesity on occurrence of DD complications [31, 32]. Overall consensus about these statements was very high, since all of them reached >80% agreement among respondents.

## 2. Course of the disease

**2.1 Symptomatic Uncomplicated Diverticular Disease (SUDD) is a distinct clinical syndrome characterized by recurrent abdominal symptoms attributed to diverticula in the absence of clinical, laboratory, or radiographic markers of overt inflammation. [EL: 1c; RG: B]**

Consensus levels of agreement: A+ 49.19%; A 37.10%; A- 11.29%; D- 0%; D 1.61%; D+ 0.81%.

**2.2 The pathophysiology of SUDD is poorly understood, with some evidence suggesting altered colonic motility, visceral hypersensitivity, microbiome alterations and/or subclinical inflammation playing etiological roles. [EL: 4; RG: D]**

Consensus levels of agreement: A+ 55.65%; A 30.65%; A- 12.10%; D- 0.81%; D 0.81%; D+ 0%.

**2.3 There is no evidence to suggest that bowel habits or a change in those habits determine the evolution to diverticulitis. [EL: 1c; RG: B]**

Consensus levels of agreement: A+ 48.49%; A 33.06%; A- 12.90%; D- 4.03%; D 0%; D+ 0.81%.

**2.4 SUDD post-acute diverticulitis is a chronic inflammatory disease with prolonged chronic symptoms, high levels of systemic serum inflammatory markers, high levels of tissue inflammatory cytokine and chronic inflammatory infiltrates in the affected colonic tissue. [E: 2C; RG: B]**

Consensus levels of agreement: A+ 49.19%; A 18.55%; A- 20.16%; D- 8.87%; D 1.81%; D+ 1.81%.

**2.5 There is still no definite evidence that rifaximin reduces acute episodes of diverticulitis. [EL: 4; RG: D]**

Consensus levels of agreement: A+ 45.57%; A 39.52%; A- 8.06%; D- 4.84%; D 1.61%; D+ 0%.

**2.6 There are some evidences that mesalazine could reduce symptoms following acute episode of diverticulitis. [EL: 3a; RG: B]**

Consensus levels of agreement: A+ 17.74%; A 49.19%; A- 28.23%; D- 1.61%; D 1.61%; D+ 1.61%.



**2.7 At present, there is no evidence that mesalazine reduces acute episodes of diverticulitis. [EL: 1c; RG: B]**

Consensus levels of agreement: A+ 52.42%; A 28.23%; A- 11.29%; D- 5.65%; D: 1.61%; D+ 0.81%.

#### Comments

These statements point out the new evidences about the evolution of diverticulosis towards occurrence of SUDD and acute diverticulitis. The first two statements define clearly that SUDD is a distinct clinical syndrome, with distinct clinical characteristics from irritable bowel syndrome (IBS) [33, 34], and have specific characteristics about cytokine expression and microbiota signature [24, 35-39]. The third statement clarify that, based on current evidences, changing of bowel habits do not seems to influence the evolution towards AD [40]. The forth statement points out patients experiencing SUDD following an episode of acute diverticulitis have persistence of inflammation in terms of histological inflammation and increased expression of cytokines, findings that underscore the risk of AD recurrence [41, 42]. The last three statements point out that, at present, there are no clear evidences on how to prevent AD occurrence and its recurrence. Neither rifaximin nor mesalazine seems to be effective on both these topics [5, 43-44], while mesalazine seems to reduce symptoms following an episode of AD [45, 46]. This because the trial design was not optimal, and this was particularly true for trials investigating mesalazine. Also the overall consensus about these statement was very high, since all of them reached >80% agreement among respondents.

### 3. Diagnosis

**3.1 No single biomarker is sensitive and specific enough to be recommended as diagnostic tool for symptomatic uncomplicated diverticular disease. [EL: 1a; GR: A]**

Consensus levels of agreement: A+ 83.87%; A 15.32%; A- 0%; D- 0%; D: 0.81%; D+ 0%.

**3.2 C-reactive protein levels >150 mg/l strongly predicts complicated diverticulitis. [EL: 1a; GR: A]**

Consensus levels of agreement: A+ 43.55%; A 50%; A- 6.45%; D- 0%; D: 0%; D+ 0%.

**3.3 Faecal Calprotectin might be useful in distinguishing symptomatic uncomplicated diverticular disease from irritable bowel syndrome, but a cut-off level needs to be identified. [EL: 3c; GR: C]**

Consensus levels of agreement: A+ 38.71%; A 45.97%; A- 8.87%; D- 0.81%; D: 2.42%; D+ 3.23%.

**3.4 Contrast-enhanced computer tomography (CE-CT) should be considered as the first-line colonic examination since it offers a more comprehensive evaluation of uncomplicated and complicated forms; CE-CT can also be used to guide therapeutic interventions. [EL 1b; GR: A]**

Consensus levels of agreement: A+ 38.71%; A 45.97%; A- 8.87%; D- 0.81%; D: 2.42%; D+ 3.23%.

**3.5 Ultrasound has slightly lower sensitivity and specificity compared to CT in the assessment of acute diverticulitis and**

**its use as the first-line diagnostic procedure - followed by CT scan in the case of inconclusive sonographic findings - may spare the use of CT in more than 50% of cases. [EL: 1a; GR: A]**

Consensus levels of agreement: A+ 55.65%; A 23.39%; A- 18.55%; D- 1.61%; D: 0.81%; D+ 0%.

**3.6 Ultrasound coupled with i.v. contrast agents (CEUS) differentiates between peri-intestinal phlegmon and abscess and demonstrates the real extension of the abscess in acute diverticulitis.**

Ultrasound-guided drainage, when feasible, is the preferable option for abscesses larger than 3 cm. [EL: 4; GR: C]

Consensus levels of agreement: A+ 50%; A 41.13%; A- 0%; D- 0.81%; D: 0%; D+ 0%.

**3.7 Ultrasound is useful to monitor the patients after the acute diverticulitis and in particular the lesions treated conservatively. [EL: 2b; GR: B]**

Consensus levels of agreement: A+ 33.87%; A 48.39%; A- 15.39%; D- 2.42%; D: 0%; D+ 0%.

**3.8 Ultrasound may be of help in detecting symptomatic uncomplicated diverticular disease (SUDD) of the colon. [EL: 4; GR: C]**

Consensus levels of agreement: A+ 27.42%; A 52.42%; A- 13.71%; D- 3.23%; D: 1.61%; D+ 1.61%.

**3.9 A prompt colonoscopy (i.e. within 12-24 h) is mandatory for diagnosis and to direct therapy in diverticular bleeding. Massive bleeding should be managed with selective angiography. [EL: 2a; GR: B]**

Consensus levels of agreement: A+ 45.97%; A 41.94%; A- 6.45%; D- 5.65%; D: 0%; D+ 0%.

**3.10. DICA endoscopic classification seems to have a predictive value on the outcome of the disease. EL: 1b; GR: B**

Consensus levels of agreement: A+ 47.58%; A 45.97%; A- 4.03%; D- 2.42%; D: 0%; D+ 0%.

#### Comments

These statements point out the new evidences about the role of diagnosis in diagnosing and managing SUDD and AD. The first three statements confirm the important predicting value of C-reactive protein (CRP) in define the presence and the severity of acute diverticulitis [47, 48], and that fecal calprotectin (FC) may be useful in differentiating between SUDD and IBS [35]. The forth statement confirms that the contrast-enhanced computer tomography is the gold standard to pose the diagnosis of AD and its complications [49]. The statements 3.5-3.8 underscore the increasing role of the intestinal ultrasound (IUS) in diagnosis both SUDD and AD, underscoring also the limit of this technique, namely that it operator-sensitive [50-52]. The statement 3.9 points out the role of colonoscopy in those people. In particular, it underscore the role of colonoscopy in managing diverticular bleeding, which is the main cause of lower gastrointestinal bleeding and linked to the advanced age and the numerous, associated comorbidities [53-55]. The last statement point out the attention on the first validated endoscopic classification on diverticulosis and

diverticular disease, called DICA (Diverticular Inflammation and Complication Assessment) [55]. This classification, very easy to use, has a significant predicting value on the outcome of the disease (57), and has also a significant interobserver agreement in real life [58]. The overall consensus about these statements was very high, since all of them reached >80% agreement among respondents.

#### 4. Medical treatment

##### **4.1 Rifaximin plus fibre is effective in reducing symptoms in SUDD patients compared to fibre alone. [EL: 2b; GR: B]**

Consensus levels of agreement: A+ 66.94%; A 28.23%; A- 3.23%; D- 1.61%; D: 0%; D+ 0%.

##### **4.2 Mesalazine is effective in reducing symptoms in SUDD patients. [EL: 1b; GR: A]**

Consensus levels of agreement: A+51.61%; A 34.68%; A- 11.29%; D- 1.61%; D: 0.81%; D+ 0%.

##### **4.3 There are some evidences that probiotics could be effective in reducing symptoms in SUDD patients [EL: 3a; GR: B]**

Consensus levels of agreement: A+32.26%; A 36.29%; A- 28.23%; D- 3.23%; D: 0%; D+ 0.81%.

#### Comments

These statements focused their attention just on the treatment of SUDD, which is still under active debate. In particular, focusing their attention on the efficacy of non-absorbable antibiotics (namely rifaximin), anti-inflammatory drugs (namely mesalazine), and probiotics. The first statement confirms that rifaximin, especially when associated with fibre, is effecting in reducing symptoms in SUDD [43, 59]. The second statement claims that mesalazine is also effective in reducing symptoms in those people and in preventing its recurrence during the follow-up [46, 60, 61]. The last statement claims that there are some interesting news in using probiotics in those people [61, 62], but data are still too heterogeneous to draw any definite conclusions. It is noteworthy the impressive overall consensus about these statements, reaching >90% agreement among respondents.

#### 5. Surgical treatment

##### **5.1 Treatment of acute uncomplicated diverticulitis (AUD) without antibiotics is safe and effective and it is not associated with worse outcomes, including need for surgery, complications, recurrence and length of hospital stay. [EL: 2b; GR: B]**

Consensus levels of agreement: A+28.23%; A 41.94%; A- 13.71%; D- 8.87%; D: 3.23%; D+ 4.03%.

##### **5.2 In Uncomplicated Acute Diverticulitis antibiotic therapy is still considered in patients immunocompromised, with severe comorbidities (ASA>2) and with sign of sepsis. [EL: 3b; GR: C]**

Consensus levels of agreement: A+79.03%; A 20.97%; A- 0%; D- 0%; D: 0%; D+ 0%.

##### **5.3 There are some evidence that high CPR level (>170 mg/ml) or a initial CT findings of fluid collection and**

**longer inflamed colon could be useful factors in selecting patients who could benefit of antibiotic treatment, but these preliminary data need to be confirmed by further studies. [EL: 4; GR: C]**

Consensus levels of agreement: A+69.35%; A 28.23%; A- 2.42%; D- 0%; D: 0%; D+ 0%.

##### **5.4 The open approach to acute diverticulitis in urgent/emergent setting should be preferred for patients with hemodynamic instability, or when an adequate expertise in colorectal laparoscopy is not available. [EL: 4; GR: B]**

Consensus levels of agreement: A+82.26%; A 14.52%; A- 3.23%; D- 0%; D: 0%; D+ 0%.

##### **5.5 Laparoscopic resection is safe and provides faster recovery in uncomplicated cases: cases; it has to be performed by well-trained surgeons. [EL: 2b; GR: B]**

Consensus levels of agreement: A+77.42%; A 20.97%; A- 1.61%; D- 0%; D: 0%; D+ 0%.

##### **5.6 Laparoscopic peritoneal lavage may be an alternative to manage purulent peritonitis Hinchey III in diverticular disease. [EL: 4; GR: B]**

Consensus levels of agreement: A+19.35%; A 50%; A- 16.94%; D- 8.87%; D: 4.84%; D+ 0%.

##### **5.7 The decision to perform elective resection after one or more episodes of AD should be undertaken on a "case-by-case" basis. [EL: 2b; GR: B]**

Consensus levels of agreement: A+71.77%; A 25%; A- 3.23%; D- 0%; D: 0%; D+ 0%.

#### Comments

These statements focused their attention mainly on the surgical treatment of treatment of AD, since SUDD has not a surgical recommendation. The first statements are dedicated to the current indication on antibiotic of in the setting of AD. The first claims that the management of acute diverticulitis without antibiotics does not increase these worse outcomes [63-68]. Therefore, the second statement confirms that antibiotics have to be used by a "case-by-case" basis [5, 66], and that some parameters (namely levels of PCR and CT findings at entry) may be predictive on the need to use antibiotics in this population (48,66). The last three statement confirms that the open or the laparoscopic approach to AD, as well as an elective resection after multiple episode of AD have to follow a "case-by-case" basis [69, 73]. It is noteworthy the impressive overall consensus about these statements, since disagreement on them among respondents was almost absent.

#### 6. Critical issues

##### **6.1 Ambulatory treatment of uncomplicated acute diverticulitis is safe, effective and applicable to patients who do not present concomitant unstable comorbid conditions; immunosuppression; cognitive, social, or psychiatric impairment; and intolerance to oral intake.**

**Outpatient management allows important cost saving to the health systems without negative influence on the quality**

**of life of patients with uncomplicated diverticulitis. [EL: 1a; GR: A]**

Consensus levels of agreement: A+60.48%; A 36.29%; A-3.23%; D- 0%; D: 0%; D+ 0%.

**6.2 Segmental Colitis Associated with Diverticulosis (SCAD) is a chronic inflammation occurring in the colon harboring diverticulosis that seems to resemble a chronic inflammatory disease rather than a complicated diverticular disease.**

**Treatment options include antibiotics (Ciproxin and metronidazole), 5-ASA and probiotics for mild cases. In severe disease the use of systemic steroids might be warranted. Anti TNF $\alpha$  treatment may be beneficial in severe disease resistant to other therapeutic options. Treatment duration might vary depending on clinical response and can last weeks-months. [EL: 2b; GR: C].**

Consensus levels of agreement: A+48.39%; A 41.13%; A-8.87%; D- 0%; D: 0%; D+ 0%.

**6.3 Diverticular inflammation is not a causative risk factor for colorectal cancer (CRC) but is an important factor that should be taken into account requiring early colonoscopy to exclude cancer. [EL: 2a; GR: B].**

Consensus levels of agreement: A+73.39%; A 22.58%; A-4.03%; D- 0%; D: 0%; D+ 0%.

*Comments*

These statements focused their attention on three topics under active debate. The first statement claims about the safety of ambulatory treatment of uncomplicated AD, which is safe and effective [73-79]. Moreover, this approach has also a significant impact on cost-saving [79]. The second statement claims that segmental colitis associated with diverticulosis (SCAD), is a chronic disease occurring in a colon harbouring diverticulosis, and that seems to be a chronic inflammatory bowel disease than a complication of DD [80-83]. This disease may be treated with a variety of treatments, from antibiotic and 5-ASA to anti-TNF $\alpha$  antibodies [84, 85]. The last statement confirms that DD is not a causative risk factor for colorectal cancer (CRC) [86, 87]. However, it should be excluded in patients after an episode of complicated acute diverticulitis, especially when the colon has not been studied never before [88]. It is noteworthy the impressive overall consensus about these statements, since any disagreement was recorded among respondents.

## CONCLUSIONS

These guidelines represent a consensus of best practice based on the available evidence as showed at the time of the 3rd International Symposium on Diverticular Disease. The statement proposed and voted during this Symposium have been developed starting from the statements voted during the 2nd International Symposium on Diverticular Disease, held in Rome on April 2016 [5], and have been conceived as an improvement of the points in which there were no clear evidence at that time. This is because these guidelines are not described in a classical way (“epidemiology”, “diagnosis”,

“treatment”, etc.), as well as no every finding of the disease has been voted or discussed. On the contrary, the sessions (and the statements, as consequence) have been designed just as improvement of that it is already clearly known. The strength of these guidelines is that the statements have been designed by several International experts using a Delphi-like process, and have been approved by a large population of physicians, involving all medical categories managing DD, and coming from European, Northern and Southern America, Australian and African countries.

They may not apply to all situations and should be interpreted in the light of specific clinical situations and resource availability. Further controlled clinical studies may be needed to clarify some aspects of these statements, and revision will definitely be needed, as new data will become available. This is particularly true not only for some medical treatments currently under active debate (in example, how to prevent acute diverticulitis recurrence), but also for some surgical aspects (example when to operate DD).

These Guidelines are not rules, but are intended to be an educational tool to provide information that may assist each medical category (general practitioners, gastroenterologists and surgeons) in providing care to patients, not as encouraging, advocating, requiring, or discouraging any particular treatment.

## REFERENCES

1. Strate LL, Modi R, Cohen E, Spiegel BM. Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. *Am J Gastroenterol* 2012;107:1486-1493. doi:10.1038/ajg.2012.194
2. Papa A, Papa V. The Economic Burden of Diverticular Disease. *J Clin Gastroenterol* 2016;50 Suppl 1:S2-S3. doi:10.1097/MCG.0000000000000598
3. Kruis W, Germer CT, Leifeld L; German Society for Gastroenterology, Digestive and Metabolic Diseases and The German Society for General and Visceral Surgery. Diverticular disease: guidelines of the german society for gastroenterology, digestive and metabolic diseases and the german society for general and visceral surgery. *Digestion* 2014;90:190-207. doi:10.1159/000367625
4. Stollman N, Smalley W, Hirano I; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the Management of Acute Diverticulitis. *Gastroenterology* 2015;149:1944-1949. doi:10.1053/j.gastro.2015.10.003
5. Tursi A, Picchio M, Elisei W, Di Mario F, Scarpignato C, Brandimarte G. Management of Patients With Diverticulosis and Diverticular Disease: Consensus Statements From the 2nd International Symposium on Diverticular Disease. *J Clin Gastroenterol* 2016;50 Suppl 1:S101-S107. doi:10.1097/MCG.0000000000000654
6. Oxford Centre for Evidence-Based Medicine. Available at: <http://www.cebm.net/index.aspx?o=5653>
7. Reichert MC, Lammert F. The genetic epidemiology of diverticulosis and diverticular disease: Emerging evidence. *United Eur Gastroenterol J* 2015;3:409-418. doi:10.1177/2050640615576676
8. Granlund J, Svensson T, Olén O, et al. The genetic influence on diverticular disease--a twin study. *Aliment Pharmacol Ther* 2012;35:1103-1107. doi:10.1111/j.1365-2036.2012.05069.x
9. Strate LL, Erichsen R, Baron JA, et al. Heritability and Familial Aggregation of Diverticular Disease: A Population-Based Study of Twins



- and Siblings. *Gastroenterology* 2013;144:736–742.e1. doi: [10.1053/j.gastro.2012.12.030](https://doi.org/10.1053/j.gastro.2012.12.030)
10. Connelly TM, Berg AS, Hegarty JP, et al. The TNFSF15 Gene Single Nucleotide Polymorphism rs7848647 Is Associated With Surgical Diverticulitis. *Ann Surg* 2014;259:1132–1137. doi:[10.1097/SLA.0000000000000232](https://doi.org/10.1097/SLA.0000000000000232)
  11. Reichert MC, Kupcinkas J, Krawczyk M, et al. A Variant of COL3A1 (rs3134646) Is associated with risk of developing diverticulosis in white men. *Dis Colon Rectum* 2018;61:604–611. doi:[10.1097/DCR.0000000000001001](https://doi.org/10.1097/DCR.0000000000001001)
  12. Sigurdsson S, Alexandersson KF, Sulem P, et al. Sequence variants in ARHGAP15, COLQ and FAM155A associate with diverticular disease and diverticulitis. *Nat Commun* 2017; 8:15789. doi:[10.1038/ncomms15789](https://doi.org/10.1038/ncomms15789)
  13. Maguire LH, Handelman SK, Du X, Chen Y, Pers TH, Speliotes EK. Genome-wide association analyses identify 39 new susceptibility loci for diverticular disease. *Nat Genet* 2018; 50:1359–1365. doi:[10.1038/s41588-018-0203-z](https://doi.org/10.1038/s41588-018-0203-z)
  14. Schafmayer C, Harrison JW, Buch S, et al. Genome-wide association analysis of diverticular disease points towards neuromuscular, connective tissue and epithelial pathomechanisms. *Gut* 2019;68:854–865. doi:[10.1136/gutjnl-2018-317619](https://doi.org/10.1136/gutjnl-2018-317619)
  15. Bassotti G, Battaglia E, Bellone G, et al. Interstitial cells of Cajal, enteric nerves, and glial cells in colonic diverticular disease. *J Clin Pathol* 2005;58:973–977. doi:[10.1136/jcp.2005.026112](https://doi.org/10.1136/jcp.2005.026112)
  16. Fornai M, Colucci R, Antonioli L, et al. Role of cyclooxygenase isoforms in the altered excitatory motor pathways of human colon with diverticular disease. *Br J Pharmacol* 2014;171:3728–3740. doi:[10.1111/bph.12733](https://doi.org/10.1111/bph.12733)
  17. Bassotti G, Villanacci V, Bernardini N, Dore MP. Diverticular Disease of the Colon: neuromuscular Function Abnormalities. *J Clin Gastroenterol* 2016;50 (Suppl 1):S6–S8. doi:[10.1097/MCG.0000000000000578](https://doi.org/10.1097/MCG.0000000000000578)
  18. Bassotti G, Battaglia E, De Roberto G, Morelli A, Tonini M, Villanacci V. Alterations in colonic motility and relationship to pain in colonic diverticulosis. *Clin Gastroenterol Hepatol* 2005;3:248–253. doi:[10.1016/s1542-3565\(04\)00614-7](https://doi.org/10.1016/s1542-3565(04)00614-7)
  19. Bassotti G, Villanacci V, Nascimbeni R, et al. The role of colonic mast cells and myenteric plexitis in patients with diverticular disease. *Int J Colorectal Dis* 2013;28:267–272. doi:[10.1007/s00384-012-1554-z](https://doi.org/10.1007/s00384-012-1554-z)
  20. Humes DJ, Simpson J, Smith J, et al. Visceral hypersensitivity in symptomatic diverticular disease and the role of neuropeptides and low grade inflammation. *Neurogastroenterol Motil* 2012;24:318–e163. doi:[10.1111/j.1365-2982.2011.01863.x](https://doi.org/10.1111/j.1365-2982.2011.01863.x)
  21. Tursi A. Endoscopic Diagnosis of Diverticulosis and Diagnosis of Symptomatic Uncomplicated Diverticular Disease of the Colon: If You Properly Classify, You Properly Make the Diagnosis. *Am J Gastroenterol* 2019;114: 1349–1350. doi: [10.14309/ajg.0000000000000293](https://doi.org/10.14309/ajg.0000000000000293)
  22. Peery AF, Keku TO, Addamo C, et al. Colonic Diverticula Are Not Associated With Mucosal Inflammation or Chronic Gastrointestinal Symptoms. *Clin Gastroenterol Hepatol* 2018;16:884–891.e1. doi:[10.1016/j.cgh.2017.05.051](https://doi.org/10.1016/j.cgh.2017.05.051)
  23. Järbrink-Sehgal ME, Rassam L, Jasim A, et al. Diverticulosis, Symptoms and Colonic Inflammation: A Population-Based Colonoscopy Study. *Am J Gastroenterol* 2019;114:500–510. doi:[10.14309/ajg.0000000000000113](https://doi.org/10.14309/ajg.0000000000000113)
  24. Humes DJ, Simpson J, Smith J, et al. Visceral hypersensitivity in symptomatic diverticular disease and the role of neuropeptides and low grade inflammation. *Neurogastroenterol Motil* 2012;24:318–e163. doi:[10.1111/j.1365-2982.2011.01863.x](https://doi.org/10.1111/j.1365-2982.2011.01863.x)
  25. Tursi A, Brandimarte G, Elisei W, et al. Assessment and grading of mucosal inflammation in colonic diverticular disease. *J Clin Gastroenterol* 2008;42:699–703. doi:[10.1097/MCG.0b013e3180653ca2](https://doi.org/10.1097/MCG.0b013e3180653ca2)
  26. Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Trichopoulos DV, Willett WC. A prospective study of diet and the risk of symptomatic diverticular disease in men. *Am J Clin Nutr* 1994;60:757–764. doi:[10.1093/ajcn/60.5.757](https://doi.org/10.1093/ajcn/60.5.757)
  27. Aldoori WH, Giovannucci EL, Rockett HR, Sampson L, Rimm EB, Willett WC. A prospective study of dietary fiber types and symptomatic diverticular disease in men. *J Nutr* 1998;128:714–719. doi:[10.1093/jn/128.4.714](https://doi.org/10.1093/jn/128.4.714)
  28. Crowe FL, Appleby PN, Allen NE, Key TJ. Diet and risk of diverticular disease in Oxford cohort of European Prospective Investigation into Cancer and Nutrition (EPIC): prospective study of British vegetarians and non-vegetarians. *BMJ* 2011;343:d4131. doi:[10.1136/bmj.d4131](https://doi.org/10.1136/bmj.d4131)
  29. Crowe FL, Balkwill A, Cairns BJ, et al. Source of dietary fibre and diverticular disease incidence: a prospective study of UK women. *Gut* 2014;63:1450–1456. doi:[10.1136/gutjnl-2013-304644](https://doi.org/10.1136/gutjnl-2013-304644)
  30. Strate LL, Keeley BR, Cao Y, Wu K, Giovannucci EL, Chan AT. Western Dietary Pattern Increases, and Prudent Dietary Pattern Decreases, Risk of Incident Diverticulitis in a Prospective Cohort Study. *Gastroenterology* 2017;152:1023–1030.e2. doi:[10.1053/j.gastro.2016.12.038](https://doi.org/10.1053/j.gastro.2016.12.038)
  31. Hjern F, Wolk A, Hakansson N. Obesity, physical inactivity, and colonic diverticular disease requiring hospitalization in women: a prospective cohort study. *Am J Gastroenterol* 2012;107:296–302. doi:[10.1038/ajg.2011.352](https://doi.org/10.1038/ajg.2011.352)
  32. Ma W, Jovani M, Liu PH, et al. Association Between Obesity and Weight Change and Risk of Diverticulitis in Women. *Gastroenterology* 2018;155:58–66.e4. doi:[10.1053/j.gastro.2018.03.057](https://doi.org/10.1053/j.gastro.2018.03.057)
  33. Cuomo R, Barbara G, Andreati P, et al. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. *Eur J Clin Invest* 2013;43:1147–1155. doi:[10.1111/eci.12152](https://doi.org/10.1111/eci.12152)
  34. Tursi A, Elisei W, Picchio M, Giorgetti GM, Brandimarte G. Moderate to severe and prolonged left lower-abdominal pain is the best symptom characterizing symptomatic uncomplicated diverticular disease of the colon: a comparison with fecal calprotectin in clinical setting. *J Clin Gastroenterol* 2015;49:218–221. doi:[10.1097/MCG.0000000000000094](https://doi.org/10.1097/MCG.0000000000000094)
  35. Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F. Faecal calprotectin in colonic diverticular disease: a case-control study. *Int J Colorectal Dis* 2009;24:49–55. doi:[10.1007/s00384-008-0595-9](https://doi.org/10.1007/s00384-008-0595-9)
  36. Tursi A, Elisei W, Brandimarte G, et al. Mucosal expression of basic fibroblastic growth factor, Syndecan 1 and tumor necrosis factor-alpha in diverticular disease of the colon: a case-control study. *Neurogastroenterol Motil* 2012;24:836–e396. doi:[10.1111/j.1365-2982.2012.01946.x](https://doi.org/10.1111/j.1365-2982.2012.01946.x)
  37. Tursi A, Mastromarino P, Capobianco D, et al. Assessment of fecal microbiota and fecal metabolome in symptomatic uncomplicated diverticular disease of the colon. *J Clin Gastroenterol* 2016;50 Suppl 1:S9–S12. doi:[10.1097/MCG.0000000000000626](https://doi.org/10.1097/MCG.0000000000000626)
  38. Barbara G, Scaioni E, Barbaro MR, et al. Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. *Gut* 2017;66:1252–1261. doi:[10.1136/gutjnl-2016-312377](https://doi.org/10.1136/gutjnl-2016-312377)
  39. Kvasnovsky CL, Leong LEX, Choo JM, et al. Clinical and symptom scores are significantly correlated with fecal microbiota features in patients with symptomatic uncomplicated diverticular disease: a pilot study. *Eur J Gastroenterol Hepatol* 2018;30:107–112. doi:[10.1097/MEG.0000000000000995](https://doi.org/10.1097/MEG.0000000000000995)



40. Gao R, Tao Y, Zhou C, et al. Exercise therapy in patients with constipation: a systematic review and meta-analysis of randomized controlled trials. *Scand J Gastroenterol* 2019;54:169-177. doi:[10.1080/00365521.2019.1568544](https://doi.org/10.1080/00365521.2019.1568544)
41. Lahat A, Necula D, Yavzori M, et al. Prolonged Recurrent Abdominal Pain is Associated With Ongoing Underlying Mucosal Inflammation in Patients who had an Episode of Acute Complicated Diverticulitis. *J Clin Gastroenterol* 2019;53:e178-e185. doi:[10.1097/MCG.0000000000000980](https://doi.org/10.1097/MCG.0000000000000980)
42. Tursi A, Elisei W, Giorgetti GM, et al. Detection of endoscopic and histological inflammation after an attack of colonic diverticulitis is associated with higher diverticulitis recurrence. *J Gastrointest Liver Dis* 2013;22:13-19.
43. Bianchi M, Festa V, Moretti A, et al. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. *Aliment Pharmacol Ther* 2011;33:902-910. doi:[10.1111/j.1365-2036.2011.04606.x](https://doi.org/10.1111/j.1365-2036.2011.04606.x)
44. Raskin JB, Kamm MA, Jamal MM, et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. *Gastroenterology* 2014;147:793-802. doi:[10.1053/j.gastro.2014.07.004](https://doi.org/10.1053/j.gastro.2014.07.004)
45. Stollman N, Magowan S, Shanahan F, Quigley EM; DIVA Investigator Group. A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. *J Clin Gastroenterol* 2013;47:621-629. doi:[10.1097/MCG.0b013e31828003f6](https://doi.org/10.1097/MCG.0b013e31828003f6)
46. Picchio M, Elisei W, Tursi A. Mesalazine to treat symptomatic uncomplicated diverticular disease and to prevent acute diverticulitis occurrence. A systematic review with meta-analysis of randomized, placebo-controlled trials. *J Gastrointest Liver Dis* 2018;27:291-297. doi:[10.15403/jgld.2014.1121.273.pic](https://doi.org/10.15403/jgld.2014.1121.273.pic)
47. Andeweg CS, Knobben L, Hendriks JC, Bleichrodt RP, van Goor H. How to diagnose acute left-sided colonic diverticulitis. Proposal for a clinical scoring system. *Ann Surg* 2011;253:940-946. doi:[10.1097/SLA.0b013e3182113614](https://doi.org/10.1097/SLA.0b013e3182113614)
48. Mäkelä JM, Klintrup K, Takala H, Rautio T. The role of C-reactive protein in prediction of the severity of acute diverticulitis in an emergency unit. *Scand J Gastroenterol* 2015;50:536-541. doi:[10.3109/00365521.2014.999350](https://doi.org/10.3109/00365521.2014.999350)
49. Ambrosetti P. Acute left-sided colonic diverticulitis: clinical expressions, therapeutic insights, and role of computed tomography. *Clin Exp Gastroenterol* 2016;9:249-257. doi:[10.2147/CEG.S110428](https://doi.org/10.2147/CEG.S110428)
50. Lameris W, Van Randen A, Bipat S, Bossuyt PM, Boermeester MA, Stoker J. Graded compression ultrasonography and computed tomography in acute colonic diverticulitis: meta-analysis of test accuracy. *Eur Radiol* 2008;18:2498-2511. doi:[10.1007/s00330-008-1018-6](https://doi.org/10.1007/s00330-008-1018-6)
51. Dirks K, Calabrese E, Dietrich CF, et al. EFSUMB Position Paper: Recommendations for Gastrointestinal Ultrasound (GIUS) in Acute Appendicitis and Diverticulitis. *Ultraschall Med* 2019;40:163-175. doi:[10.1055/a-0824-6952](https://doi.org/10.1055/a-0824-6952)
52. Van Randen A, Lameris W, van Es HW, et al. A comparison of the accuracy of ultrasound and computed tomography in common diagnoses causing acute abdominal pain. *Eur Radiol* 2011;21:1535-1545. doi:[10.1007/s00330-011-2087-5](https://doi.org/10.1007/s00330-011-2087-5)
53. Longstreth GF. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population-based study. *Am J Gastroenterol* 1997;92:419-424.
54. Nagata N, Niikura R, Aoki T, et al. Colonic diverticular hemorrhage associated with the use of nonsteroidal anti-inflammatory drugs, low-dose aspirin, antiplatelet drugs, and dual therapy. *J Gastroenterol Hepatol* 2014;19:1786-1793. doi:[10.1111/jgh.12595](https://doi.org/10.1111/jgh.12595)
55. Wong Kee Song LM, Baron TH. Endoscopic management of acute lower gastrointestinal bleeding. *Am J Gastroenterol* 2008;103:1881-1887.
56. Tursi A, Brandimarte G, Di Mario F, et al. Development and validation of an endoscopic classification of diverticular disease of the colon: the DICA classification. *Dig Dis* 2015;33:68-76. doi:[10.1159/000366039](https://doi.org/10.1159/000366039)
57. Tursi A, Brandimarte G, Di Mario F, et al; DICA Collaborative Group. Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study. *United European Gastroenterol J* 2016;4:604-613. doi:[10.1177/2050640615617636](https://doi.org/10.1177/2050640615617636)
58. Tursi A, Brandimarte G, Di Mario F, et al; DICA Italian Group. The "DICA" endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists. *J Gastrointest Liver Dis* 2019;28:23-27. doi:[10.15403/jgld.2014.1121.281.dic](https://doi.org/10.15403/jgld.2014.1121.281.dic)
59. Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicenter double-blind placebo-controlled trial. *Aliment Pharmacol Ther* 1995;9:33-39. doi:[10.1111/j.1365-2036.1995.tb00348.x](https://doi.org/10.1111/j.1365-2036.1995.tb00348.x)
60. Kruis W, Meier E, Schumacher M, et al; German SAG-20 Study Group. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon--a placebo-controlled study. *Aliment Pharmacol Ther* 2013;37:680-690. doi:[10.1111/apt.12248](https://doi.org/10.1111/apt.12248)
61. Tursi A, Brandimarte G, Elisei W, et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study. *Aliment Pharmacol Ther* 2013;38:741-751. doi:[10.1111/apt.12463](https://doi.org/10.1111/apt.12463)
62. Kvasnovsky CL, Bjarnason I, Donaldson AN, Sherwood RA, Papagrigoriadis S. A randomized double-blind placebo-controlled trial of a multi-strain probiotic in treatment of symptomatic uncomplicated diverticular disease. *Inflammopharmacology* 2017 May 20. doi:[10.1007/s10787-017-0363-y](https://doi.org/10.1007/s10787-017-0363-y)
63. Emile SH, Elfeki H, Sakr A, Shalaby M. Management of acute uncomplicated diverticulitis without antibiotics: a systematic review, meta-analysis, and meta-regression of predictors of treatment failure. *Tech Coloproctol* 2018;22:499-509. doi:[10.1007/s10151-018-1817-y](https://doi.org/10.1007/s10151-018-1817-y)
64. Mocanu V, Dang JT, Switzer N, et al. The role of antibiotics in acute uncomplicated diverticulitis: A systematic review and meta-analysis. *Am J Surg* 2018;216:604-609. doi:[10.1016/j.amjsurg.2018.01.039](https://doi.org/10.1016/j.amjsurg.2018.01.039)
65. Desai M, Fathallah J, Nutalapati V, Saligram S. Antibiotics Versus No Antibiotics for Acute Uncomplicated Diverticulitis: A Systematic Review and Meta-Analysis. *Dis Colon Rectum* 2019;62:1005-1012. doi:[10.1097/DCR.0000000000001324](https://doi.org/10.1097/DCR.0000000000001324)
66. Azhar N, Kulstad H, Pålsson B, Kurt Schultz J, Lydrup ML, Buchwald P. Acute uncomplicated diverticulitis managed without antibiotics - difficult to introduce a new treatment protocol but few complications. *Scand J Gastroenterol* 2019;54:64-68. doi:[10.1080/00365521.2018.1552987](https://doi.org/10.1080/00365521.2018.1552987)
67. Tandon A, Fretwell VL, Nunes QM, Rooney PS. Antibiotics versus no antibiotics in the treatment of acute uncomplicated diverticulitis - a systematic review and meta-analysis. *Colorectal Dis* 2018 Jan 11. doi:[10.1111/codi.14013](https://doi.org/10.1111/codi.14013)
68. Au S, Aly EH. Treatment of Uncomplicated Acute Diverticulitis Without Antibiotics: A Systematic Review and Meta-Analysis. *Dis Colon Rectum* 2019;62:1533-1547. doi:[10.1097/DCR.0000000000001330](https://doi.org/10.1097/DCR.0000000000001330)
69. Di Saverio S. Emergency laparoscopy: a new emerging discipline for treating abdominal emergencies attempting to minimize costs and

- invasiveness and maximize outcomes and patients' comfort. *J Trauma Acute Care Surg* 2014;77:338-350. doi:[10.1097/TA.0000000000000288](https://doi.org/10.1097/TA.0000000000000288)
70. Klarenbeek BR, Veenhof AA, Bergamaschi R, et al. Laparoscopic sigmoid resection for diverticulitis decreases major morbidity rates: a randomized control trial: short-term results of the Sigma Trial. *Ann Surg* 2009;249:39-44. doi:[10.1097/SLA.0b013e31818e416a](https://doi.org/10.1097/SLA.0b013e31818e416a)
71. Gervaz P, Inan I, Perneger T, Schiffer E, Morel P. A prospective, randomized, single-blind comparison of laparoscopic versus open sigmoid colectomy for diverticulitis. *Ann Surg* 2010;252:3-8. doi:[10.1097/SLA.0b013e3181dbb5a5](https://doi.org/10.1097/SLA.0b013e3181dbb5a5)
72. Cirocchi R, Farinella E, Trastulli S, Sciannameo F, Audisio RA. Elective sigmoid colectomy for diverticular disease. Laparoscopic vs open surgery: a systematic review. *Colorectal Dis* 2012;14:671-683. doi:[10.1111/j.1463-1318.2011.02666.x](https://doi.org/10.1111/j.1463-1318.2011.02666.x)
73. Kohl A, Rosenberg J, Bock D, et al. Two-year results of the randomized clinical trial DILALA comparing laparoscopic lavage with resection as treatment for perforated diverticulitis. *Br J Surg* 2018;105:1128-1134. doi:[10.1002/bjs.10839](https://doi.org/10.1002/bjs.10839)
74. Isacson D, Thorisson A, Andreasson K, Nikberg M, Smedh K, Chabok A. Outpatient, non-antibiotic management in acute uncomplicated diverticulitis: a prospective study. *Int J Colorectal Dis* 2015;30:1229-1234. doi:[10.1007/s00384-015-2258-y](https://doi.org/10.1007/s00384-015-2258-y)
75. Biondo S, Golda T, Kreisler E, et al. Outpatient versus hospitalization management for uncomplicated diverticulitis: a prospective, multicenter randomized clinical trial (DIVERTrial). *Ann Surg* 2014;259:38-44. doi:[10.1097/SLA.0b013e3182965a11](https://doi.org/10.1097/SLA.0b013e3182965a11)
76. Sánchez-Velázquez P, Grande L, Pera M. Outpatient treatment of uncomplicated diverticulitis: a systematic review. *Eur J Gastroenterol Hepatol* 2016;28:622-627. doi:[10.1097/MEG.0000000000000610](https://doi.org/10.1097/MEG.0000000000000610)
77. Bolkenstein HE, Draaisma WA, van de Wall B, Consten E, Broeders I. Treatment of acute uncomplicated diverticulitis without antibiotics: risk factors for treatment failure. *Int J Colorectal Dis* 2018;33:863-869. doi:[10.1007/s00384-018-3055-1](https://doi.org/10.1007/s00384-018-3055-1)
78. Rottier SJ, van Dijk ST, Ünlü Ç, van Geloven AAW, Schreurs WH, Boermeester MA. Complicated Disease Course in Initially Computed Tomography-Proven Uncomplicated Acute Diverticulitis. *Surg Infect (Larchmt)* 2019;20:453-459. doi:[10.1089/sur.2018.289](https://doi.org/10.1089/sur.2018.289)
79. Mills AM, Holena DN, Kallan MJ, Carr BG, Reinke CE, Kelz RR. Effect of insurance status on patients admitted for acute diverticulitis. *Colorectal Dis* 2013;15:613-620. doi:[10.1111/codi.12066](https://doi.org/10.1111/codi.12066)
80. Tursi A. Segmental colitis associated with diverticulosis: complication of diverticular disease or autonomous entity? *Dig Dis Sci* 2011;56:27-34. doi:[10.1007/s10620-010-1230-5](https://doi.org/10.1007/s10620-010-1230-5)
81. Imperiali G, Meucci G, Alvisi C, et al. Segmental colitis associated with diverticula: a prospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). *Am J Gastroenterol* 2000;95:1014-1016.
82. Mann NS, Hoda KK. Segmental colitis associated with diverticulosis: systematic evaluation of 486 cases with meta-analysis. *Hepatogastroenterology* 2012;59:2119-2112.
83. Ludeman L, Shepherd NA. What is diverticular colitis? *Pathology* 2002;34:568-572. doi:[10.1080/0031302021000035974](https://doi.org/10.1080/0031302021000035974)
84. Schembri J, Bonello J, Christodoulou DK, Katsanos KH, Ellul P. Segmental colitis associated with diverticulosis: is it the coexistence of colonic diverticulosis and inflammatory bowel disease? *Ann Gastroenterol* 2017;30:257-261. doi:[10.20524/aog.2017.0126](https://doi.org/10.20524/aog.2017.0126)
85. Tursi A, Elisei W, Giorgetti GM, et al. Segmental colitis associated with diverticulosis: a 5-year follow-up. *Int J Colorectal Dis* 2012;27:179-185. doi:[10.1007/s00384-011-1296-3](https://doi.org/10.1007/s00384-011-1296-3)
86. Huang WY, Lin CC, Jen YM, et al. Association between colonic diverticular disease and colorectal cancer: a nationwide population-based study. *Clin Gastroenterol Hepatol* 2014;12:1288-1294. doi:[10.1016/j.cgh.2013.11.039](https://doi.org/10.1016/j.cgh.2013.11.039)
87. Mortensen LQ, Burcharth J, Andresen K, Pommergaard HC, Rosenberg J. An 18-Year nationwide cohort study on the association between diverticulitis and colon cancer. *Ann Surg* 2017;265:954-959. doi:[10.1097/SLA.0000000000001794](https://doi.org/10.1097/SLA.0000000000001794)
88. Meyer J, Orci LA, Combescure C, et al. Risk of Colorectal Cancer in Patients With Acute Diverticulitis: A Systematic Review and Meta-analysis of Observational Studies. *Clin Gastroenterol Hepatol* 2019;17:1448-1456.e17. doi:[10.1016/j.cgh.2018.07.031](https://doi.org/10.1016/j.cgh.2018.07.031)